bullish
China Population Policies Impact on Healthcare Companies Series - Part 3
1k Views05 Jan 2024 10:32
SUMMARY
- Starting from November 1st 2023, Guangxi Zhuang Autonomous Region will include some therapeutic assisted reproductive medical services in the payment scope of basic medical insurance and work-related injury insurance funds.
- Livzon’s 23Q3 performance was below expectations, which is related to China’s anti-corruption campaign started from 23H2. Considering the Chairman's proposal to repurchase shares, we should be more patient with Livzon.
- BGI is still digesting the impact of COVID revenue, and would experience a performance low point in 2023.However, BGI belongs to the direction of national key science and technology projects.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- China Population Policies Impact on Healthcare Companies Series – Part 419 Apr 2024
- WuXi XDC Cayman (2268.HK) - Would It Be An "Oasis in the Desert"?03 Jan 2024
- China Population Policies Impact on Healthcare Companies Series – Part 203 Oct 2023
- China Population Policies Impact on Healthcare Companies Series - Part 118 Jul 2023
x